Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM512 in moderate to severe atopic dermatitis
NCT06553209Phase 1Completed
- Sponsor
- Keymed Biosciences
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CM512 in atopic dermatitis (AD) (7 arms), sponsored by Keymed Biosciences. Primary endpoint: Adverse Events up to 169 days. Started Sep 2024; status: completed.
02
Drugs
CM512
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06553209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553209.